Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SNCAIP antisense RNA 3 (SNCAIP-AS3) is a long non-coding RNA classified as a natural antisense transcript (NAT) arising from the SNCAIP locus[1]. It is not a receptor, enzyme, or traditional druggable target, but rather regulates gene expression, most likely in cis, at the RNA level by mechanisms common to antisense RNAs such as interference with transcription, modulation of splicing, and/or regulation of mRNA stability[3][4][6]. There is limited functional characterization of SNCAIP-AS3 specifically; most published data focus on related antisense RNAs at the SNCA or SNCAIP loci. Currently, SNCAIP-AS3 does not have a direct, validated role as a therapeutic target, nor are there any known drug interactions or established roles in disease[1]. The target appears to be included due to mistaken identity or lack of target validation (it is not a protein, not a therapeutic target, and evidence for biological function is sparse). Additional context and justifications: - SNCAIP-AS3 is annotated as a non-coding RNA; no evidence suggests it encodes a functional protein or is a pharmacological target[1]. - "Antisense RNA" molecules such as SNCAIP-AS3 can regulate their sense gene via transcriptional interference, RNA duplex formation, chromatin remodeling, or modulation of mRNA stability[3][4][6]. - SNCAIP-AS3 does not appear as a known drug target in pharmacological databases, and no drugs are reported to interact with it. - Related natural antisense transcripts (e.g., SNCA-AS1) have shown involvement in neuronal functions and neurodegenerative disease models, but SNCAIP-AS3's specific role is not established. - SNCAIP-AS3 is sometimes confused with protein-coding genes or mistakenly labeled as "hypothetical protein MGC32805," but no protein product has been verified. In summary, SNCAIP-AS3 is a poorly characterized non-coding antisense transcript, not a validated therapeutic target, and its inclusion in a target list is most likely an error or the result of mistaken data interpretation[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SNCAIP antisense RNA 3 (SNCAIP-AS3).